SCHEMBL29908705

SCHEMBL29908705

Cc1ccc(C2(C)CC(C)(C)c3ccc(C)cc3O2)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 2/20 0.54
TRPA1 O75762 4/20 0.36
CNR2 P34972 9/20 0.36
CNR1 P21554 8/20 0.36
TRPV1 Q8NER1 2/20 0.36
TRPV3 Q8NET8 2/20 0.36
TRPV4 Q9HBA0 2/20 0.36
TRPV2 Q9Y5S1 2/20 0.36
SLC6A2 P23975 2/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2B6 P20813 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
OPRM1 P35372 1/20 0.34
CYP2J2 P51589 1/20 0.34
CYP1B1 Q16678 1/20 0.34
LMNA P02545 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665594 1.00 FTO (0.54) FTOTRPA1CNR2CNR1TRPV1
Acetic Acid SCHEMBL5042300 0.93 FTO (0.48) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL24124089 0.93 FTO (0.50) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL7522231 0.90 FTO (0.53) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL9008421 0.90 FTO (0.52) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL7520930 0.90 FTO (0.52) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL12251392 0.84 FTO (0.42) FTOTRPA1CNR2CNR1TRPV1
SCHEMBL30717253 0.83 FTO (0.55) FTOCNR2LMNAHTR2BTDP1
SCHEMBL24299405 0.83 FTO (0.55) FTOCNR2LMNAHTR2BTDP1
SCHEMBL772979 0.83 FTO (0.55) FTOCNR2LMNAHTR2BTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170161-A1 INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF RISEN (SHANGHAI) MEDICINAL TECHNOLOGY CO., LTD. (CN) 2025-05-29 US disclosed
US-20240197603-A1 METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS INST NAT SANTE RECH MED (FR) 2024-06-20 US disclosed
WO-2022208123-A1 METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170161-A1 INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF INHA, IGF2BP1, IGF2BP2 FTO 2654/4885TRPA1 4880/4885CNR2 4835/4885
US-20240197603-A1 METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS SLC9A5, SLC25A3, SLC30A5 FTO 649/4885TRPA1 2598/4885CNR2 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.